Literature DB >> 20220138

Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo.

Justin Legleiter1, Emily Mitchell, Gregor P Lotz, Ellen Sapp, Cheping Ng, Marian DiFiglia, Leslie M Thompson, Paul J Muchowski.   

Abstract

Huntington disease (HD) is caused by an expansion of more than 35-40 polyglutamine (polyQ) repeats in the huntingtin (htt) protein, resulting in accumulation of inclusion bodies containing fibrillar deposits of mutant htt fragments. Intriguingly, polyQ length is directly proportional to the propensity for htt to form fibrils and the severity of HD and is inversely correlated with age of onset. Although the structural basis for htt toxicity is unclear, the formation, abundance, and/or persistence of toxic conformers mediating neuronal dysfunction and degeneration in HD must also depend on polyQ length. Here we used atomic force microscopy to demonstrate mutant htt fragments and synthetic polyQ peptides form oligomers in a polyQ length-dependent manner. By time-lapse atomic force microscopy, oligomers form before fibrils, are transient in nature, and are occasionally direct precursors to fibrils. However, the vast majority of fibrils appear to form by monomer addition coinciding with the disappearance of oligomers. Thus, oligomers must undergo a major structural transition preceding fibril formation. In an immortalized striatal cell line and in brain homogenates from a mouse model of HD, a mutant htt fragment formed oligomers in a polyQ length-dependent manner that were similar in size to those formed in vitro, although these structures accumulated over time in vivo. Finally, using immunoelectron microscopy, we detected oligomeric-like structures in human HD brains. These results demonstrate that oligomer formation by a mutant htt fragment is strongly polyQ length-dependent in vitro and in vivo, consistent with a causative role for these structures, or subsets of these structures, in HD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20220138      PMCID: PMC2863238          DOI: 10.1074/jbc.M109.093708

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation.

Authors:  K Nozaki; O Onodera; H Takano; S Tsuji
Journal:  Neuroreport       Date:  2001-10-29       Impact factor: 1.837

2.  New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins.

Authors:  J Ko; S Ou; P H Patterson
Journal:  Brain Res Bull       Date:  2001 Oct-Nov 1       Impact factor: 4.077

3.  Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment.

Authors:  Paul J Muchowski; Ke Ning; Crislyn D'Souza-Schorey; Stanley Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

4.  Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.

Authors:  Melinda M Zeron; Oskar Hansson; Nansheng Chen; Cheryl L Wellington; Blair R Leavitt; Patrik Brundin; Michael R Hayden; Lynn A Raymond
Journal:  Neuron       Date:  2002-03-14       Impact factor: 17.173

5.  Amyloid-like features of polyglutamine aggregates and their assembly kinetics.

Authors:  Songming Chen; Valerie Berthelier; J Bradley Hamilton; Brian O'Nuallain; Ronald Wetzel
Journal:  Biochemistry       Date:  2002-06-11       Impact factor: 3.162

6.  Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization.

Authors:  Michelle A Poirier; Huilin Li; Jed Macosko; Shuowei Cai; Mario Amzel; Christopher A Ross
Journal:  J Biol Chem       Date:  2002-08-08       Impact factor: 5.157

7.  Mutational analysis of the structural organization of polyglutamine aggregates.

Authors:  Ashwani K Thakur; Ronald Wetzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

8.  Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction.

Authors:  Zheng-Hong Qin; Yumei Wang; Ellen Sapp; Benjamin Cuiffo; Erich Wanker; Michael R Hayden; Kimberly B Kegel; Neil Aronin; Marian DiFiglia
Journal:  J Neurosci       Date:  2004-01-07       Impact factor: 6.167

9.  Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation.

Authors:  Songming Chen; Frank A Ferrone; Ronald Wetzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-19       Impact factor: 11.205

Review 10.  Polyglutamines placed into context.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Neuron       Date:  2003-06-05       Impact factor: 17.173

View more
  89 in total

1.  Dynamic imaging by fluorescence correlation spectroscopy identifies diverse populations of polyglutamine oligomers formed in vivo.

Authors:  Monica Beam; M Catarina Silva; Richard I Morimoto
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

2.  Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool.

Authors:  Maya A Olshina; Lauren M Angley; Yasmin M Ramdzan; Jinwei Tang; Michael F Bailey; Andrew F Hill; Danny M Hatters
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

Review 3.  Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.

Authors:  Ronald Wetzel
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

4.  Studying polyglutamine aggregation in Caenorhabditis elegans using an analytical ultracentrifuge equipped with fluorescence detection.

Authors:  Bashkim Kokona; Carrie A May; Nicole R Cunningham; Lynn Richmond; F Jay Garcia; Julia C Durante; Kathleen M Ulrich; Christine M Roberts; Christopher D Link; Walter F Stafford; Thomas M Laue; Robert Fairman
Journal:  Protein Sci       Date:  2015-12-21       Impact factor: 6.725

5.  Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.

Authors:  Mingchen Chen; Peter G Wolynes
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-11       Impact factor: 11.205

Review 6.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

7.  Reversible aggregation of PABPN1 pre-inclusion structures.

Authors:  Vered Raz; Tsion Abraham; Erik W van Zwet; Roeland W Dirks; Hans J Tanke; Silvère M van der Maarel
Journal:  Nucleus       Date:  2011 May-Jun       Impact factor: 4.197

8.  p62 plays a protective role in the autophagic degradation of polyglutamine protein oligomers in polyglutamine disease model flies.

Authors:  Yuji Saitoh; Nobuhiro Fujikake; Yuma Okamoto; H Akiko Popiel; Yusuke Hatanaka; Morio Ueyama; Mari Suzuki; Sébastien Gaumer; Miho Murata; Keiji Wada; Yoshitaka Nagai
Journal:  J Biol Chem       Date:  2014-12-05       Impact factor: 5.157

Review 9.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

10.  Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.

Authors:  Eva L Morozko; Joseph Ochaba; Sarah J Hernandez; Alice Lau; Isabella Sanchez; Iliana Orellana; Lexi Kopan; Joshua Crapser; Janet H Duong; Julia Overman; Silvia Yeung; Joan S Steffan; Jack Reidling; Leslie M Thompson
Journal:  J Huntingtons Dis       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.